Bristol-Myers Squibb Co.

NYSE:BMY   2:24:32 PM EDT
+1.19 (+1.60%)

U.S. FDA Approves Bristol Myers Squibb'S Car T Cell Therapy Breyanzi For Relapsed Large B-Cell Lymphoma

Published: 06/24/2022 23:14 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. FDA Approves Bristol Myers Squibb’s Car T Cell Therapy Breyanzi® for Relapsed Or Refractory Large B-cell Lymphoma After One Prior Therapy.
Bmy - Single Infusion of Breyanzi Significantly Outperformed Nearly 30-year Standard of Care.